Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopulegol SCHEMBL8814498 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8816208 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL18828953 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL15013625 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8813812 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL5043480 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20903638 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20903648 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL20681722 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| Isopulegol SCHEMBL8618394 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717973-B2 | Method for the biocatalytic cyclization of terpenes and cyclase mutants employable therein | BASF SE (DE) | 2020-07-21 | — | — | US | disclosed |
| US-10421703-B2 | Ruthenium-phenol catalysts for transfer hydrogenation reactions | BASF SE (DE) | 2019-09-24 | — | — | US | disclosed |
| EP-2640835-B1 | METHOD FOR THE BIOCATALYTIC CYCLISATION OF TERPENES AND CYCLASE MUTANTS WHICH CAN BE USED IN SAID METHOD | BASF SE (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20190119665-A1 | METHOD FOR THE BIOCATALYTIC CYCLIZATION OF TERPENES AND CYCLASE MUTANTS EMPLOYABLE THEREIN | BASF SE (DE) | 2019-04-25 | — | — | US | disclosed |
| US-20180037530-A1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | BASF SE (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037530-A1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | BASF SE (DE) | 2018-02-08 | — | — | US | disclosed |
| US-9856199-B2 | Method for producing menthones from isopulegol in the gas phase | BASF SE (DE) | 2018-01-02 | — | — | US | disclosed |
| US-9790157-B2 | Ruthenium-phenol catalysts and method of preparing menthone from isopulegol | BASF SE (REITSTÖTTER, KINZEBACH & PARTNER) (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9790157-B2 | Ruthenium-phenol catalysts and method of preparing menthone from isopulegol | BASF SE (REITSTÖTTER, KINZEBACH & PARTNER) (DE) | 2017-10-17 | — | — | US | disclosed |
| EP-2892869-B1 | METHOD FOR THE PREPARATION OF MENTHONE FROM ISOPULEGOL | BASF SE (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-8932839-B2 | Method for the biocatalytic cyclization of terpenes and cyclase mutants employable therein | BASF SE (DE) | 2015-01-13 | — | — | US | disclosed |
| US-8932839-B2 | Method for the biocatalytic cyclization of terpenes and cyclase mutants employable therein | BASF SE (DE) | 2015-01-13 | — | — | US | disclosed |
| US-20140323585-A1 | MICROBIAL COMPOSITION | DOW GLOBAL TECHNOLOGY LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140073817-A1 | METHOD FOR PREPARING MENTHONE FROM ISOPULEGOL | BASF SE (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073817-A1 | METHOD FOR PREPARING MENTHONE FROM ISOPULEGOL | BASF SE (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2014037264-A1 | METHOD FOR PRODUCING MENTHONE FROM ISOPULEGOL | BASF SE (DE) | 2014-03-13 | — | — | WO | disclosed |
| EP-2706054-A1 | Method for the preparation of menthone from isopulegol | BASF SE (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20120237991-A1 | Method for the biocatalytic cyclization of terpenes and cyclase mutants employable therein | BASF SE (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120237991-A1 | Method for the biocatalytic cyclization of terpenes and cyclase mutants employable therein | BASF SE (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012066059-A2 | METHOD FOR THE BIOCATALYTIC CYCLISATION OF TERPENES AND CYCLASE MUTANTS WHICH CAN BE USED IN SAID METHOD | BASF SE (DE) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037530-A1 | RUTHENIUM-PHENOL CATALYSTS FOR TRANSFER HYDROGENATION REACTIONS | HPD, ICMT, MDH2 | TRPA1 1185/4885TRPM8 1287/4885CA1 3062/4885 |
| US-20140073817-A1 | METHOD FOR PREPARING MENTHONE FROM ISOPULEGOL | MSMO1, SQLE, MDH2 | TRPA1 2524/4885TRPM8 1215/4885CA1 2645/4885 |
| US-10421703-B2 | Ruthenium-phenol catalysts for transfer hydrogenation reactions | HPD, ICMT, MDH2 | TRPA1 1185/4885TRPM8 1287/4885CA1 3062/4885 |
| US-20140323585-A1 | MICROBIAL COMPOSITION | CD14, DRD3, JUND | TRPA1 1090/4885TRPM8 940/4885CA1 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.